Regulatory information
Macimorelin (also known as Ghryvelin) received marketing authorisation from the European Medicines Agency for diagnosing adult growth hormone deficiency in January 2019 (EU/1/18/1337/001).
Macimorelin (also known as Ghryvelin) received marketing authorisation from the European Medicines Agency for diagnosing adult growth hormone deficiency in January 2019 (EU/1/18/1337/001).